Really new drug - just approved earlier this year.

I believe there is at least two members of the group that are currently taking it.

In theory it should work a little better than the others in it's class (GLP-1) since it includes a second (agonist) that effects GIP.

The two hormones (GLP-1 produced by the small intestine and GIP produced by the stomach) tell the pancreas to turn on the insulin in response to a meal.

Drugs in this class attempt to keep the insulin flowing a little longer than what it naturally would. Another hormone (DPP-4) turns it off so we don't go low and kill ourselves.

In any even, since it is making two, instead of one, insulin influencing hormones work a little harder, it "should" would at least a little better than the others in the class (Ozempic et al).

It will probably take 3 to 5 years of "actual use" for all the data to show how much better it works if it is in fact better at all.

No. Metaformin. I am prediabetes still.